메이저 바카라사이트 유니88벳 Biologics (CEO John Rim) announced on May 22 that it will spin off its biosimilar operations to form a new entity, 메이저 바카라사이트 유니88벳 Epis Holdings. The restructuring separates its contract development and manufacturing (CDMO) business from its biosimilar unit, currently operated by 메이저 바카라사이트 유니88벳 Bioepis.

Effective October 1, 메이저 바카라사이트 유니88벳 Biologics will focus exclusively on its CDMO operations, while 메이저 바카라사이트 유니88벳 Epis Holdings will assume full ownership of 메이저 바카라사이트 유니88벳 Bioepis and manage all biosimilar-related activities. The spin-off is designed to eliminate potential conflicts of interest between the two businesses and enable tailored investment strategies for each. The company emphasized that the move will strengthen both corporate governance and shareholder value.

Shareholder approval for the spin-off is scheduled for September 16. Following the split, 메이저 바카라사이트 유니88벳 Biologics and 메이저 바카라사이트 유니88벳 Epis Holdings will be listed separately on October 29. Kyung-Ah Kim, CEO of 메이저 바카라사이트 유니88벳 Bioepis, will also serve as CEO of the newly formed 메이저 바카라사이트 유니88벳 Epis Holdings.

As part of the spin-off structure, shareholders will be allocated shares in both companies according to their current holdings, at a ratio of 0.6503913 shares of 메이저 바카라사이트 유니88벳 Biologics to 0.3496087 shares of 메이저 바카라사이트 유니88벳 Epis Holdings. Trading of 메이저 바카라사이트 유니88벳 Biologics stock will be suspended from September 29 to October 28.

Post spin-off, 메이저 바카라사이트 유니88벳 Biologics will operate as a pure-play CDMO, advancing a three-pronged strategy: expanding manufacturing capacity, diversifying its product portfolio, and strengthening its global production network. The company also plans to invest in new areas such as antibody-drug conjugates (ADCs), adeno-associated viruses (AAVs), and pre-filled syringes (PFS).

메이저 바카라사이트 유니88벳 Epis Holdings will focus on accelerating biosimilar development through 메이저 바카라사이트 유니88벳 Bioepis, targeting a pipeline of over 20 biosimilar candidates. The company will also invest in next-generation modalities and platform technologies.

CEO John Rim commented, “This decision enables us to adapt swiftly to a rapidly evolving global market. By focusing and specializing, we aim to enhance our competitiveness and accelerate our growth into a top-tier global biopharmaceutical leader.”